{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["GAS5", "H19", "Long non-coding RNAs", "Metformin", "T2D"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36334247", "DateCompleted": {"Year": "2023", "Month": "02", "Day": "02"}, "DateRevised": {"Year": "2023", "Month": "02", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "11", "Day": "05"}], "Language": ["eng"], "ELocationID": ["10.1007/s43440-022-00427-3"], "Journal": {"ISSN": "2299-5684", "JournalIssue": {"Volume": "75", "Issue": "1", "PubDate": {"Year": "2023", "Month": "Feb"}}, "Title": "Pharmacological reports : PR", "ISOAbbreviation": "Pharmacol Rep"}, "ArticleTitle": "Effect of metformin on the long non-coding RNA expression levels in type 2 diabetes: an in vitro and clinical trial study.", "Pagination": {"StartPage": "189", "EndPage": "198", "MedlinePgn": "189-198"}, "Abstract": {"AbstractText": ["It has been suggested that the anti-hyperglycemic effect of metformin could be associated with its impact on long non-coding RNA (lncRNA) expression levels. Accordingly, in the current study, we evaluated the effect of metformin on the expression of H19, MEG3, MALAT1, and GAS5 in in vitro and in vivo situations.", "The effect of hyperglycemia and metformin treatment on the lncRNAs expression level was evaluated in HepG2 cells. A total of 179 age- and sex-matched subjects, including 88 newly diagnosed patients with type 2 diabetes (T2D) and 91 healthy volunteers, were included in the case-control phase of the study. Moreover, 40 newly diagnosed patients participated in the study's open-labeled non-controlled clinical trial phase. The expression levels of lncRNA in HepG2 cells and whole blood samples were determined using QRT-PCR.", "In vitro results showed that hyperglycemia induced H19 and MALAT1 and decreased GAS5 expression levels. Moreover, metformin decreased H19 and increased GAS5 expression in high glucose-treated cells. Case-control study findings revealed that the circulating levels of H19, MALAT1, and MEG3 were significantly\u00a0elevated in T2D patients compared to the control subjects. Finally, results showed that the level of circulating H19 levels decreased while GAS5 increased in T2D patients after taking metformin for 2\u00a0months.", "The results of the current study provided evidence that metformin could exert its effect in the treatment of T2D by altering the expression levels of H19 and GAS5."], "CopyrightInformation": "\u00a9 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran."}], "LastName": "Parvar", "ForeName": "Seyedeh Nasrin", "Initials": "SN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran."}, {"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran."}], "LastName": "Mirzaei", "ForeName": "Ali", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}], "LastName": "Zare", "ForeName": "Ali", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran."}, {"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran."}], "LastName": "Doustimotlagh", "ForeName": "Amir Hossein", "Initials": "AH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Student Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran."}], "LastName": "Nikooei", "ForeName": "Shekoofeh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Internal Medicine Department of Yasuj Medical School, Yasuj, Iran."}], "LastName": "Arya", "ForeName": "Arash", "Initials": "A"}, {"Identifier": ["0000-0001-7384-4034"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Iran's National Elites Foundation, Tehran, Iran. behnam.alipour@yums.ac.ir."}, {"Identifier": [], "Affiliation": "Department of Laboratory Sciences, Faculty of Paramedicine, Yasuj University of Medical Sciences, Yasuj, Iran. behnam.alipour@yums.ac.ir."}], "LastName": "Alipoor", "ForeName": "Behnam", "Initials": "B"}], "GrantList": [{"GrantID": "960429", "Agency": "Yasuj University of Medical Sciences", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmacol Rep", "NlmUniqueID": "101234999", "ISSNLinking": "1734-1140"}, "ChemicalList": [{"RegistryNumber": "9100L32L2N", "NameOfSubstance": "Metformin"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Long Noncoding"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Metformin"}, {"QualifierName": ["drug therapy", "genetics"], "DescriptorName": "Diabetes Mellitus, Type 2"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "RNA, Long Noncoding"}, {"QualifierName": [], "DescriptorName": "Case-Control Studies"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88\u201398.", "ArticleIdList": ["10.1038/nrendo.2017.151"]}, {"Citation": "Franks PW. Gene\u00a0\u00d7\u00a0environment interactions in type 2 diabetes. Curr Diab Rep. 2011;11(6):552\u201361.", "ArticleIdList": ["10.1007/s11892-011-0224-9"]}, {"Citation": "Ghasemi H, Sabati Z, Ghaedi H, Salehi Z, Alipoor B. Circular RNAs in \u03b2-cell function and type 2 diabetes-related complications: a potential diagnostic and therapeutic approach. Mol Biol Rep. 2019;46(5):5631\u201343.", "ArticleIdList": ["10.1007/s11033-019-04937-x"]}, {"Citation": "Rezaeinejad F, Mirzaei A, Khalvati B, Sabz G, Alipoor B. Circulating expression levels of CircHIPK3 and CDR1as circular-RNAs in type 2 diabetes patients. Mol Biol Rep. 2022;49(1):131\u20138.", "ArticleIdList": ["10.1007/s11033-021-06850-8"]}, {"Citation": "Alipoor B, Nikouei S, Rezaeinejad F, Malakooti-Dehkordi S, Sabati Z, Ghasemi H. Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets. J Endocrinol Invest. 2021;44(10):2015\u201341.", "ArticleIdList": ["10.1007/s40618-021-01559-8"]}, {"Citation": "Pope C, Mishra S, Russell J, Zhou Q, Zhong X-B. Targeting H19, an imprinted long non-coding RNA, in hepatic functions and liver diseases. Diseases. 2017;5(1):11.", "ArticleIdList": ["10.3390/diseases5010011"]}, {"Citation": "Zhang Y, Liu J, Lv Y, Zhang C, Guo S. LncRNA meg3 suppresses hepatocellular carcinoma in vitro and vivo studies. Am J Transl Res. 2019;11(7):4089."}, {"Citation": "Zhang N, Geng T, Wang Z, Zhang R, Cao T, Camporez JP, et al. Elevated hepatic expression of H19 long noncoding RNA contributes to diabetic hyperglycemia. JCI insight. 2018. https://doi.org/10.1172/jci.insight.120304 .", "ArticleIdList": ["10.1172/jci.insight.120304"]}, {"Citation": "Zhong T, Men Y, Lu L, Geng T, Zhou J, Mitsuhashi A, et al. Metformin alters DNA methylation genome-wide via the H19/SAHH axis. Oncogene. 2017;36(17):2345\u201354.", "ArticleIdList": ["10.1038/onc.2016.391"]}, {"Citation": "Saleh AA, Kasem HE, Zahran ES, El-Hefnawy SM. Cell-free long non-coding RNAs (LY86-AS1 & HCG27_201and GAS5) as biomarkers for pre-diabetes and type 2 DM in Egypt. Biochem Biophys Rep. 2020;23: 100770."}, {"Citation": "You L, Wang N, Yin D, Wang L, Jin F, Zhu Y, et al. Downregulation of long noncoding RNA Meg3 affects insulin synthesis and secretion in mouse pancreatic beta cells. J Cell Physiol. 2016;231(4):852\u201362.", "ArticleIdList": ["10.1002/jcp.25175"]}, {"Citation": "Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487\u201393."}, {"Citation": "Apostolova N, Iannantuoni F, Gruevska A, Muntane J, Rocha M, Victor VM. Mechanisms of action of metformin in type 2 diabetes: effects on mitochondria and leukocyte\u2013endothelium interactions. Redox Biol. 2020;34: 101517.", "ArticleIdList": ["10.1016/j.redox.2020.101517"]}, {"Citation": "Out M, Top WM, Lehert P, Schalkwijk CA, Stehouwer CD, Kooy A. Long-term treatment with metformin in type 2 diabetes and vitamin D levels: a post-hoc analysis of a randomized placebo-controlled trial. Diabetes Obes Metab. 2018;20(8):1951\u20136.", "ArticleIdList": ["10.1111/dom.13327"]}, {"Citation": "Guo J, Zhou Y, Cheng Y, Fang W, Hu G, Wei J, et al. Metformin-induced changes of the coding transcriptome and non-coding RNAs in the livers of non-alcoholic fatty liver disease mice. Cell Physiol Biochem. 2018;45(4):1487\u2013505.", "ArticleIdList": ["10.1159/000487575"]}, {"Citation": "Wang Y, Tang H, Ji X, Zhang Y, Xu W, Yang X, et al. Expression profile analysis of long non-coding RNAs involved in the metformin-inhibited gluconeogenesis of primary mouse hepatocytes. Int J Mol Med. 2018;41(1):302\u201310."}, {"Citation": "Zare M, Panahi G, Koushki M, Mostafavi-Pour Z, Meshkani R. Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b. Arch Physiol Biochem. 2022;128(2):333\u201340.", "ArticleIdList": ["10.1080/13813455.2019.1680700"]}, {"Citation": "Lalau J-D, Kajbaf F, Bennis Y, Hurtel-Lemaire A-S, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018;41(3):547\u201353.", "ArticleIdList": ["10.2337/dc17-2231"]}, {"Citation": "Tandon T, Dubey AK, Srivastava S, Manocha S, Arora E, Hasan N. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. J Family Med Primary Care. 2019;8(3):955.", "ArticleIdList": ["10.4103/jfmpc.jfmpc_22_19"]}, {"Citation": "Shiferaw WS, Akalu TY, Desta M, Kassie AM, Petrucka PM, Aynalem YA. Effect of educational interventions on knowledge of the disease and glycaemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2021;11(12): e049806.", "ArticleIdList": ["10.1136/bmjopen-2021-049806"]}, {"Citation": "Rashid M, Shahzad M, Mahmood S, Khan K. Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus. Pak J Med Sci. 2019;35(1):71.", "ArticleIdList": ["10.12669/pjms.35.1.100"]}, {"Citation": "Liu Y, Liu X, Zhang S, Zhu Q, Fu X, Chen H, et al. Association of anthropometric indices with the development of diabetes among hypertensive patients in China: a cohort study. Front Endocrinol. 2021. https://doi.org/10.3389/fendo.2021.736077 .", "ArticleIdList": ["10.3389/fendo.2021.736077"]}, {"Citation": "Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101\u20138.", "ArticleIdList": ["10.1038/nprot.2008.73"]}, {"Citation": "Ramakers C, Ruijter JM, Deprez RHL, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett. 2003;339(1):62\u20136.", "ArticleIdList": ["10.1016/S0304-3940(02)01423-4"]}, {"Citation": "Huang H-Y, Lin Y-C-D, Li J, Huang K-Y, Shrestha S, Hong H-C, et al. miRTarBase 2020: updates to the experimentally validated microRNA\u2013target interaction database. Nucleic Acids Res. 2020;48(D1):D148-D54."}, {"Citation": "Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;10."}, {"Citation": "Rines AK, Sharabi K, Tavares CD, Puigserver P. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat Rev Drug Discov. 2016;15(11):786\u2013804.", "ArticleIdList": ["10.1038/nrd.2016.151"]}, {"Citation": "Kim YD, Park K-G, Lee Y-S, Park Y-Y, Kim D-K, Nedumaran B, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008;57(2):306\u201314.", "ArticleIdList": ["10.2337/db07-0381"]}, {"Citation": "Yang L, Jiang J. GAS5 regulates RECK expression and inhibits invasion potential of HCC cells by sponging miR-135b. BioMed Res Int. 2019. https://doi.org/10.1155/2019/2973289 .", "ArticleIdList": ["10.1155/2019/2973289"]}, {"Citation": "Leti F, Legendre C, Still CD, Chu X, Petrick A, Gerhard GS, et al. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. Transl Res. 2017;190(25\u201339): e21."}, {"Citation": "Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586\u201393.", "ArticleIdList": ["10.1007/s00125-017-4336-x"]}, {"Citation": "Shu L, Hou X, Song G, Wang C, Ma H. Comparative analysis of long non-coding RNA expression profiles induced by resveratrol and metformin treatment for hepatic insulin resistance. Int J Mol Med. 2021;48(5):1\u201314.", "ArticleIdList": ["10.3892/ijmm.2021.5039"]}, {"Citation": "Kulkarni AS, Brutsaert EF, Anghel V, Zhang K, Bloomgarden N, Pollak M, et al. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell. 2018;17(2): e12723.", "ArticleIdList": ["10.1111/acel.12723"]}, {"Citation": "de Kreutzenberg SV, Ceolotto G, Cattelan A, Pagnin E, Mazzucato M, Garagnani P, et al. Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. Nutr Metab Cardiovasc Dis. 2015;25(7):686\u201393."}, {"Citation": "Tseng H-H, Chen Y-Z, Chou N-H, Chen Y-C, Wu C-C, Liu L-F, et al. Metformin inhibits gastric cancer cell proliferation by regulation of a novel Loc100506691-CHAC1 axis. Mol Therapy-Oncol. 2021;22:180\u201394.", "ArticleIdList": ["10.1016/j.omto.2021.08.006"]}, {"Citation": "Chen Z, Wei H, Zhao X, Xin X, Peng L, Ning Y, et al. Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP-2 and MMP-9 via H19/miR-29b-3p and AKT/mTOR/autophagy signaling pathways. J Cell Physiol. 2019;234(11):19964\u201376.", "ArticleIdList": ["10.1002/jcp.28594"]}, {"Citation": "Shu C, Yan D, Chen C, Mo Y, Wu L, Gu J, et al. Metformin exhibits its therapeutic effect in the treatment of pre-eclampsia via modulating the Met/H19/miR-148a-5p/P28 and Met/H19/miR-216-3p/EBI3 signaling pathways. Int Immunopharmacol. 2019;74: 105693.", "ArticleIdList": ["10.1016/j.intimp.2019.105693"]}, {"Citation": "Zeng J, Zhu L, Liu J, Zhu T, Xie Z, Sun X, et al. Metformin protects against oxidative stress injury induced by ischemia/reperfusion via regulation of the lncRNA-H19/miR-148a-3p/Rock2 axis. Oxidat Med Cell Longev. 2019. https://doi.org/10.1155/2019/8768327 .", "ArticleIdList": ["10.1155/2019/8768327"]}, {"Citation": "Aminimoghaddam S, Fooladi B, Noori M, Klashami ZN, Hamidi AK, Amoli MM. The effect of metformin on expression of long non-coding RNA H19 in endometrial cancer. Med J Islamic Rep Iran. 2021. https://doi.org/10.47176/mjiri.35.155 ."}, {"Citation": "Gao Y, Wu F, Zhou J, Yan L, Jurczak MJ, Lee H-Y, et al. The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells. Nucleic Acids Res. 2014;42(22):13799\u2013811.", "ArticleIdList": ["10.1093/nar/gku1160"]}, {"Citation": "Tello-Flores VA, Valladares-Salgado A, Ram\u00edrez-Vargas MA, Cruz M, del-Moral-Hern\u00e1ndez O, Cahua-Pablo J\u00c1, et al. Altered levels of MALAT1 and H19 derived from serum or serum exosomes associated with type-2 diabetes. Non-coding RNA Res. 2020;5(2):71\u20136."}, {"Citation": "Jiang Y, Qian T, Li S, Xie Y, Tao M. Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer. Ann Transl Med. 2022;10(6):366.", "ArticleIdList": ["10.21037/atm-22-795"]}, {"Citation": "Jin F, Wang N, Zhu Y, You L, Wang L, De W, et al. Downregulation of long noncoding RNA Gas5 affects cell cycle and insulin secretion in mouse pancreatic \u03b2 cells. Cell Physiol Biochem. 2017;43(5):2062\u201373.", "ArticleIdList": ["10.1159/000484191"]}, {"Citation": "Wang S, Ai H, Liu L, Zhang X, Gao F, Zheng L, et al. Micro-RNA-27a/b negatively regulates hepatic gluconeogenesis by targeting FOXO1. Am J Physiol Endocrinol Metab. 2019;317(5):E911\u201324.", "ArticleIdList": ["10.1152/ajpendo.00190.2019"]}, {"Citation": "Li B, Fan J, Chen N. A novel regulator of type II diabetes: MicroRNA-143. Trends Endocrinol Metab. 2018;29(6):380\u20138.", "ArticleIdList": ["10.1016/j.tem.2018.03.019"]}, {"Citation": "Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E, et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care. 2014;37(5):1375\u201383.", "ArticleIdList": ["10.2337/dc13-1847"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "8", "Day": "2"}, {"Year": "2022", "Month": "10", "Day": "25"}, {"Year": "2022", "Month": "10", "Day": "22"}, {"Year": "2022", "Month": "11", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "11", "Day": "5", "Hour": "12", "Minute": "29"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36334247", "10.1007/s43440-022-00427-3", "10.1007/s43440-022-00427-3"]}}], "PubmedBookArticle": []}